Literature DB >> 6356227

The design, synthesis and development of a new class of potent antineoplastic anthraquinones.

C C Cheng, R K Zee-Cheng.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6356227     DOI: 10.1016/s0079-6468(08)70217-0

Source DB:  PubMed          Journal:  Prog Med Chem        ISSN: 0079-6468


× No keyword cloud information.
  6 in total

1.  The pharmacokinetics and toxicity of the anthrapyrazole anti-cancer drug CI-941 in the mouse: a guide for rational dose escalation in patients.

Authors:  M A Graham; D R Newell; B J Foster; A H Calvert
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  1,8-Bis(tos-yloxy)-9,10-anthraquinone.

Authors:  Paweł Niedziałkowski; Damian Trzybiński; Artur Sikorski; Tadeusz Ossowski
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2009-12-04

3.  Investigation of the interaction of cardiotoxic anticancer agents using the fetal mouse heart organ culture system.

Authors:  B F Kimler; R D Rethorst; G G Cox
Journal:  Invest New Drugs       Date:  1986       Impact factor: 3.850

4.  Structural modification study of anthracyclinones: synthesis and biological activity of several derivatives of eta-pyrromycinone.

Authors:  D F Liu; H Xiong; C C Cheng
Journal:  Pharm Res       Date:  1992-06       Impact factor: 4.200

5.  Assessment of DNA double-strand breaks and gammaH2AX induced by the topoisomerase II poisons etoposide and mitoxantrone.

Authors:  Daniel J Smart; H Dorota Halicka; Gabriele Schmuck; Frank Traganos; Zbigniew Darzynkiewicz; Gary M Williams
Journal:  Mutat Res       Date:  2008-03-25       Impact factor: 2.433

Review 6.  Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent.

Authors:  L H Patterson
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.